Senti Biosciences Holdings, Inc. (SNTI) company profile
Close on Nov 17, 2026Market cap $3.02MP/E –Yield –
About Senti Biosciences
Biological Products, (No Diagnostic Substances), SIC 2836
Senti Biosciences is a clinical-stage biotechnology company that develops cell and gene therapies using synthetic biology and proprietary gene circuit technologies. The company programs cells with biological logic to target and destroy cancer cells while sparing healthy tissue. Its lead product candidate is SENTI-202, an off-the-shelf chimeric antigen receptor natural killer cell therapy designed to treat relapsed or refractory hematological malignancies, including acute myeloid leukemia. In addition to internal oncology initiatives, Senti Biosciences maintains preclinical programs in solid tumors and partners with BlueRock Therapeutics to develop cell therapies for regenerative medicines.
The company conducts clinical trials in the United States and Australia. Senti Biosciences has its contract clinical manufacturing performed in Alameda, California, following the sale of manufacturing assets and sublease of its facility to GeneFab. The company holds worldwide licensing agreements with the National Cancer Institute for chimeric antigen receptor technologies.
Summary of the business section of Senti Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Senti Biosciences Holdings, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 2 Corporate Drive, First Floor 94080
- Phone
- (650) 239-2030
- Website
- sentibio.com
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Francisco, CA,
Stock & identifiers
- Ticker
- SNTI
- Former tickers
- DYNS until Jun 9, 2022
- Exchange
- Nasdaq
- IPO date
- May 26, 2021
- Shares outstanding
- 31M, Jul 31, 2026
- Public float
- $53.20M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Jul 18, 2024; 1-for-10 reverse, Aug 15, 2022
- SEC CIK
- 1854270
- CUSIP
- 816944102
- ISIN
- US8169441024
- FIGI
- BBG021Y8RQQ5
- Share class FIGI
- BBG021Y8RQS3
- EIN
- 86-2437900
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Timothy K. Lu | CEO, Director | 587,949 |
| Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | 87,890 |
| John Harry Cross III | Chief Financial Officer | – |
| Bryan Daniel Baum | Director | – |
| Donald F. Tang | Director | 10,368 |
| Edward T. Mathers | Director | – |
| James J. Collins | Director | 176,130 |
| Fran Schulz | Director | – |
| Brenda Cooperstone | Director | – |
| Feng Hsiung | Director | – |
Executive compensation, fiscal 2024
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Timothy Lu Chief Executive Officer | $618.76K | $140.76K | $159.14K | $442.41K | $12.03K | $930.69K | -45% |
| Kanya Rajangam President, Head of Research and Development and Chief Medical Officer | $526.79K | $46.46K | $52.70K | $265.50K | $1.76K | $858.77K | +37% |
| Yvonne Li Former Chief Financial Officer | – | – | – | – | $547.54K | $547.54K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Corporate history
Events identified from SEC filings
See a number that looks wrong?